Glomerular and tubular effects of dapagliflozin, eplerenone and their combination in patients with chronic kidney disease: A post-hoc analysis of the ROTATE-3 study.
albuminuria
chronic kidney disease
dapagliflozin
eplerenone
mineralocorticoid receptor antagonist
sodium-glucose co-transporter 2 inhibitors
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
05 Nov 2023
05 Nov 2023
Historique:
revised:
01
10
2023
received:
05
06
2023
accepted:
10
10
2023
medline:
6
11
2023
pubmed:
6
11
2023
entrez:
5
11
2023
Statut:
aheadofprint
Résumé
Sodium-glucose co-transporter 2 inhibitors and mineralocorticoid receptor antagonists reduce albuminuria and the risk of kidney failure. The aim of this study was to investigate the effects of both agents alone and in combination on markers of the glomerular endothelial glycocalyx and tubular function. This post-hoc analysis utilized data of the ROTATE-3 study, a randomized cross-over study in 46 adults with chronic kidney disease and urinary albumin excretion ≥100 mg/24 h, who were treated for 4 weeks with dapagliflozin, eplerenone or its combination. The effects of dapagliflozin, eplerenone and the combination on outcome measures such as heparan sulphate, neuro-hormonal markers and tubular sodium handling were assessed with mixed repeated measures models. The mean percentage change from baseline in heparan sulphate after 4 weeks treatment with dapagliflozin, eplerenone or dapagliflozin-eplerenone was -34.8% (95% CI -52.2, -10.9), -5.9% (95% CI -32.5, 31.3) and -28.1% (95% CI -48.4, 0.1) respectively. The mean percentage change from baseline in plasma aldosterone was larger with eplerenone [38.9% (95% CI 2.8, 87.7)] and dapagliflozin-eplerenone [32.2% (95% CI -1.5, 77.4)], compared with dapagliflozin [-12.5% (95% CI -35.0, 17.8)], respectively. Mean percentage change from baseline in copeptin with dapagliflozin, eplerenone or dapagliflozin-eplerenone was 28.4% (95% CI 10.7, 49.0), 4.2% (95% CI -10.6, 21.4) and 23.8% (95% CI 6.6, 43.9) respectively. Dapagliflozin decreased proximal absolute sodium reabsorption rate by 455.9 mmol/min (95% CI -879.2, -32.6), while eplerenone decreased distal absolute sodium reabsorption rate by 523.1 mmol/min (95% CI -926.1, -120.0). Dapagliflozin-eplerenone decreased proximal absolute sodium reabsorption [-971.0 mmol/min (95% CI -1411.0, -531.0)], but did not affect distal absolute sodium reabsorption [-9.2 mmol/min (95% CI -402.0, 383.6)]. Dapagliflozin and eplerenone exert different effects on markers of glomerular and tubular function supporting the hypothesis that different mechanistic pathways may account for their kidney protective effects.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Références
Oshima M, Neuen BL, Li JW, et al. Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: a post hoc analysis from the CREDENCE trial. J Am Soc Nephrol. 2020;31(12):2925-2936. doi:10.1681/ASN.2020050723
Provenzano M, Puchades MJ, Garofalo C, et al. ROTATE-3: albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized cross-over clinical trial. J Am Soc Nephrol. 2022;33(8):1569-1580. doi:10.1681/ASN.2022020207/-/DCSUPPLEMENTAL
Rabelink TJ, De Zeeuw D. The glycocalyx-linking albuminuria with renal and cardiovascular disease. Nat Rev Nephrol. 2015;11(11):667-676. doi:10.1038/NRNEPH.2015.162
Garsen M, Rops A, Rabelink TJ, Berden JHM, Van Der Vlag J. The role of heparanase and the endothelial glycocalyx in the development of proteinuria. Nephrol Dial Transplant. 2014;29(1):49-55. doi:10.1093/NDT/GFT410
Butler MJ, Ramnath R, Kadoya H, et al. Aldosterone induces albuminuria via matrix metalloproteinase-dependent damage of the endothelial glycocalyx. Kidney Int. 2019;95(1):94-107. doi:10.1016/J.KINT.2018.08.024
Li X, Preckel B, Hermanides J, Hollmann MW, Zuurbier CJ, Weber NC. Amelioration of endothelial dysfunction by sodium glucose co-transporter 2 inhibitors: pieces of the puzzle explaining their cardiovascular protection. Br J Pharmacol. 2022;179(16):4047-4062. doi:10.1111/BPH.15850
Cooper S, Teoh H, Campeau MA, Verma S, Leask RL. Empagliflozin restores the integrity of the endothelial glycocalyx in vitro. Mol Cell Biochem. 2019;459(1-2):121-130. doi:10.1007/S11010-019-03555-2
Marton A, Kaneko T, Kovalik JP, et al. Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation. Nat Rev Nephrol. 2021;17(1):65-77. doi:10.1038/S41581-020-00350-X
Jalleh R, Torpy DJ. The emerging role of copeptin. Clin Biochem Rev. 2021;42(1):17-25. doi:10.33176/AACB-20-00001
R Core Team. R: A Language and Enironment for Statistical Computing. 2017 https://www.R-project.org
Fu J, Lee K, Chuang PY, Liu Z, He JC. Glomerular endothelial cell injury and cross talk in diabetic kidney disease. Am J Physiol Renal Physiol. 2015;308:287-297. doi:10.1152/ajprenal.00533.2014
Nieuwdorp M, Mooij HL, Kroon J, et al. Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes. 2006;55(4):1127-1132. doi:10.2337/DIABETES.55.04.06.DB05-1619
Lytvyn Y, Bjornstad P, Katz A, et al. SGLT2 inhibition increases serum copeptin in young adults with type 1 diabetes. Diabetes Metab. 2020;46(3):203-209. doi:10.1016/J.DIABET.2019.11.006
Mordi NA, Mordi IR, Singh JS, McCrimmon RJ, Struthers AD, Lang CC. Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: the RECEDE-CHF trial. Circulation. 2020;142(18):1713-1724. doi:10.1161/CIRCULATIONAHA.120.048739
Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. DAPA-CKD trial: dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436-1446. doi:10.1056/NEJMOA2024816/SUPPL_FILE/NEJMOA2024816_DATA-SHARING.PDF
Koshino A, Schechter M, Sen T, et al. Interleukin-6 and cardiovascular and kidney outcomes in patients with type 2 diabetes: new insights from CANVAS. Diabetes Care. 2022;45(11):2644-2652. doi:10.2337/DC22-0866/687934/DC220866.PDF
Sen T, Koshino A, Neal B, et al. Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: a post hoc mediation analysis of the CANVAS trial. Diabetes Obes Metab. 2022;24(10):1950-1956. doi:10.1111/DOM.14779
Pitt B. Mineralocorticoid receptor antagonists for the treatment of hypertension and the metabolic syndrome. Hypertension. 2015;65(1):41-42. doi:10.1161/HYPERTENSIONAHA.114.04117
Van Loo L, Allegaert K, Levtchenko E, Zhang Z, Staessen JA, Raaijmakers A. Perfused boundary region as biomarker for endothelial integrity in former preterms in adolescence. Pediatric Research. 2023;93(7):1936-1942. doi:10.1038/s41390-022-02321-3